Protein delivery for retinal diseases: from basic considerations to clinical applications.

Area of Science:

• Ophthalmology
• Biotechnology
• Drug Delivery

Background:

• The eye's unique structure allows for targeted protein therapies, with intravitreous injections being a safe and effective method.
• Ranibizumab, an anti-VEGF antibody fragment (Fab), is a standard treatment for wet age-related macular degeneration (AMD), proving the concept of protein administration in the vitreous.
• Various biomolecules, including antibodies, peptides, and growth factors, show therapeutic potential in animal models for ocular diseases.

Purpose of the Study:

• To review current knowledge on protein delivery for treating eye diseases.
• To explore novel non-viral gene therapy technologies for ocular drug delivery.
• To identify areas for optimizing treatment regimens and enhancing the efficacy of protein-based therapies.

Main Methods:

• Review of existing literature on protein pharmacokinetics within the eye.
• Analysis of current therapeutic protein applications in ophthalmology.
• Exploration of emerging non-viral gene therapy technologies for ocular drug delivery.

Main Results:

• Intravitreous protein administration is feasible and effective for retinal diseases.
• Understanding protein penetration, distribution, elimination, and metabolism is crucial for optimizing delivery.
• Novel drug delivery systems are needed for controlled and sustained release of therapeutic proteins.

Conclusions:

• Protein-based therapies hold significant promise for treating ocular diseases.
• Further research into ocular pharmacokinetics and advanced drug delivery systems is essential.
• Non-viral gene therapy presents a promising avenue for future ocular treatment strategies.